We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Suggests Endpoint Validator for LGS Artificial Pancreas
FDA Suggests Endpoint Validator for LGS Artificial Pancreas
June 24, 2011
The FDA is recommending that readings from continuous glucose monitors (CGM) be used to determine if trials for artificial pancreas devices are reaching their endpoints, despite its concerns about the accuracy of the method in this context.